1. Home
  2. Search

Search

Search results

374 results found

Parkinson's Foundation Prepares for 10th Annual Moving Day

News: April 23, 2024
USF Health and Parkinson's Foundation Team up for Moving Day Tampa Bay "This Saturday marks the 10th annual Parkinson’s Moving Day in Tampa Bay, and hundreds of people who have been affected by the disease will join together in a walk to raise money and awareness. “About a year ago, I was diagnosed...

Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled Trial.

Publication: Journal Article
Comella, CL, J Jankovic, RA Hauser, AT Patel, MD Banach, E Ehler, D Vitarella, RG Rubio, and TM Gross. 2024. “Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled Trial.”. Neurology. 2024 Feb 27;102(4):e208091. Doi: 10.1212/WNL.0000000000208091. Epub 2024 Jan 31. PMID: 38295339.

Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesia. 2022 Oct 20;13:846126. doi: 10.3389/fneur.2022.846126. eCollection 2022. PMID: 36341088

Publication: Journal Article
Pahwa, R, S Fox, RA Hauser, S Isaacson, J Lytle, R Johnson, L Llorens, AE Formella, and CM Tanner. 2022. “Clinically Important Change on the Unified Dyskinesia Rating Scale Among Patients With Parkinson’s Disease Experiencing Dyskinesia. 2022 Oct 20;13:846126. Doi: 10.3389/Fneur.2022.846126. ECollection 2022. PMID: 36341088”. Front Neurol.

Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial. 2022 Dec;21(12):1099-1109. doi: 10.. PMID: 36402160

Publication: Journal Article
Soileau, MJ, J Aldred, K Budur, N Fisseha, VS Fung, A Jeong, TE Kimber, et al. 2022. “Safety and Efficacy of Continuous Subcutaneous Foslevodopa-Foscarbidopa in Patients With Advanced Parkinson’s Disease: a Randomised, Double-Blind, Active-Controlled, Phase 3 Trial. 2022 Dec;21(12):1099-1109. Doi: 10. PMID: 36402160”. Lancet Neurol.

Parkinson Study Group NILO-PD Investigators and Collaborators (including Hauser RA). Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol 2021;78:312-320.

Publication: Journal Article
Simuni, T, B Fiske, K Merchant, CS Coffey, E Klingner, C Caspell-Garcia, DE Lafontant, et al. 2021. “Parkinson Study Group NILO-PD Investigators and Collaborators (including Hauser RA). Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol 2021;78:312-320.”. JAMA Neurol.

Expediting telehealth use in clinical research studies: recommendations for overcoming barriers in North America. NPJ Parkinsons Dis 2021;7:34. doi: 10.1038/s41531-021-00177-8.PMID: 33846349

Publication: Journal Article
Naito, A, AM Wills, TF Tropea, A Ramirez-Zamora, RA Hauser, D Martino, TH Turner, and . 2021. “Expediting Telehealth Use in Clinical Research Studies: Recommendations for Overcoming Barriers in North America. NPJ Parkinsons Dis 2021;7:34. Doi: 10.1038/S41531-021-00177-8.PMID: 33846349”. NP J Parkinsons Dis.

Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson's Disease and Dyskinesia. Neurol Ther. 2021 Jun;10(1):307-320. doi: 10.1007/s40120-021-00246-3

Publication: Journal Article
Mehta, SH, R Pahwa, CM Tanner, RA Hauser, and R Johnson. 2021. “Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients With Parkinson’s Disease and Dyskinesia. Neurol Ther. 2021 Jun;10(1):307-320. Doi: 10.1007/S40120-021-00246-3”. Neurol Ther.